Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOPHYL vs ACCURBRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that causes bronchodilation primarily through inhibition of phosphodiesterase (PDE) and antagonism of adenosine receptors. It also has mild anti-inflammatory effects and enhances mucociliary clearance.
Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.
Treatment of symptoms and prevention of asthma,Treatment of chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
FDA-approved: Treatment of COPD exacerbations,Off-label: Acute asthma exacerbations
300 mg orally every 6 hours or 400-600 mg extended-release orally every 12-24 hours; intravenous loading dose 5-6 mg/kg over 20-30 minutes, then continuous infusion 0.4-0.6 mg/kg/h
Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.
Terminal elimination half-life: Adults nonsmokers: 6–12 h (mean 8.7 h); adult smokers: 4–5 h; children: 3–5 h; neonates: 20–30 h; hepatic cirrhosis: up to 30 h. Half-life increases with congestive heart failure, fever, and concurrent CYP1A2 inhibitors (e.g., cimetidine, fluvoxamine).
Terminal elimination half-life: 8-12 hours (healthy adults), prolonged to 15-20 hours in hepatic impairment. Clinical context: Supports twice-daily dosing in most patients.
Primarily metabolized by hepatic CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism is saturable, leading to non-linear pharmacokinetics.
Ipratropium: minimally metabolized via hydrolysis and conjugation; Albuterol: primarily metabolized by catechol-O-methyltransferase (COMT) and sulfation.
Renal: 10% unchanged in adults (higher in neonates). Hepatic metabolism to inactive metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid) excreted renally; fecal excretion <5%.
Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
40% bound, primarily to albumin.
85-90% bound to albumin.
0.3–0.7 L/kg (mean 0.45 L/kg). Higher Vd in neonates (0.6–0.9 L/kg) and patients with cirrhosis. Vd approximates total body water; distribution is rapid into well-perfused tissues, less into adipose tissue.
0.8-1.2 L/kg (wide distribution into tissues, including lungs).
Oral immediate-release: 96%–100% (almost complete). Oral sustained-release: 80%–100% (variable due to formulation-dependent release; food may increase rate but not extent for some products). Rectal: variable, approximately 80–90% (solution/suppository dependent).
Oral: 60-80% (first-pass metabolism reduces bioavailability).
No dose adjustment required for GFR > 10 m L/min; for GFR < 10 m L/min, reduce dose by 50% and monitor serum levels
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing oral dose by 50% or extending interval due to accumulation of acetylcysteine metabolites.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: avoid use or use with extreme caution and monitor levels
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential increased exposure.
Initial 5 mg/kg/day in divided doses every 6-8 hours, titrate based on serum levels; typical maintenance: 1-12 years: 20 mg/kg/day (max 800 mg/day), >12 years: 16 mg/kg/day (max 900 mg/day)
Inhalation: Infants and children: 1-2 m L of 20% solution or 2-4 m L of 10% solution nebulized three to four times daily. Oral: Not typically recommended for chronic use; for acetaminophen overdose, weight-based dosing is used.
Start at lower end of dosing range (e.g., 300 mg/day extended-release) with frequent monitoring due to decreased clearance; avoid doses exceeding 400 mg/day without serum level guidance
No specific dose adjustment; monitor for adverse effects such as bronchospasm or nausea. Use with caution in elderly with renal impairment (refer to renal adjustment).
No FDA black box warning for theophylline.
No FDA boxed warning exists for this combination product.
Narrow therapeutic index; monitor serum levels. Risk of cardiac arrhythmias and seizures, especially at high levels. Use with caution in patients with cardiac disease, hepatic impairment, or those receiving other methylxanthines.
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension), worsening of narrow-angle glaucoma, urinary retention, hypokalemia, and immediate hypersensitivity reactions.
Hypersensitivity to theophylline or any component of the formulation. Concurrent use of other methylxanthines.
Hypersensitivity to ipratropium, albuterol, or atropine; history of anaphylaxis to soya lecithin or related food products; narrow-angle glaucoma; prostatic hyperplasia or bladder neck obstruction (relative).
High-carbohydrate, low-protein diets can increase theophylline toxicity by reducing clearance. Charcoal-broiled meats and cruciferous vegetables (broccoli, Brussels sprouts, kale) may increase metabolism, potentially reducing efficacy. Avoid large amounts of caffeine-containing products (coffee, tea, cola, energy drinks) as they can exacerbate CNS and cardiac adverse effects.
High-fat meals can increase absorption of theophylline; take on an empty stomach or with light snack for consistent effect. Avoid large amounts of charcoal-broiled foods as they may decrease drug levels. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) can potentiate side effects such as nervousness, tremor, and insomnia. Charbroiled meats and cruciferous vegetables (broccoli, Brussels sprouts) may induce metabolism and reduce effectiveness. Grapefruit juice may increase theophylline levels; avoid concurrent use.
Theophylline is not considered a major human teratogen. First trimester: Limited data show no increased risk of major malformations above baseline. Second and third trimesters: No known teratogenic effects; however, neonatal withdrawal (irritability, jitteriness, apnea) may occur with third-trimester exposure. High maternal levels may be associated with fetal tachycardia and intrauterine growth restriction.
No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.
Theophylline is excreted into breast milk with a milk-to-plasma ratio of approximately 0.7. Infant exposure is estimated at 1-10% of maternal weight-adjusted dose. Caution is advised; monitor infant for irritability or jitteriness. The American Academy of Pediatrics considers it compatible with breastfeeding, but risk-benefit assessment should be individualized.
Not known if excreted in human breast milk. Caution advised; consider developmental benefits vs risks. M/P ratio not available.
Theophylline clearance decreases in the third trimester, leading to prolonged half-life. Dose reduction of 20-30% may be required to avoid toxicity. Monitor serum levels frequently (at least every 2-4 weeks) and adjust dose to maintain therapeutic concentrations. Postpartum, clearance returns to prepregnancy levels within 2-4 weeks, requiring upward dose adjustment.
No dose adjustment routinely recommended; however, increased clearance may require monitoring for therapeutic effect.
Theophylline has a narrow therapeutic index (5-15 mcg/m L). Monitor serum levels closely, especially when interacting drugs (e.g., cimetidine, fluoroquinolones, macrolides) are added or removed. Use with caution in patients with hepatic impairment, heart failure, or COPD exacerbation as clearance decreases. Cigarette smoking induces metabolism, requiring dose adjustments. Slow IV infusion over 20-30 minutes to avoid hypotension and arrhythmias.
Accurbron (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L. Hepatic metabolism is highly variable; monitor levels closely in patients with liver impairment, heart failure, or those on interacting drugs. Smoking induces metabolism, requiring higher doses. Use with caution in elderly and patients with seizure disorders or peptic ulcer disease. Do not crush or chew extended-release tablets.
Take exactly as prescribed; do not change dose or stop without consulting your doctor.,Avoid smoking or use of nicotine products as they alter theophylline levels.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Limit caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects.,Store medication at room temperature away from moisture and heat.,Keep regular appointments for blood level monitoring.
Take exactly as prescribed; do not change dose without doctor approval.,Do not crush or chew sustained-release tablets.,Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report any symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, seizures.,Smoking or quitting smoking can affect theophylline levels; inform your doctor about any changes in smoking habits.,Keep regular appointments for blood tests to monitor drug levels.,Avoid taking other medications, including over-the-counter drugs and herbal supplements, without consulting your doctor.
"Theophylline, a cytochrome P450 (CYP) 1A2 substrate and inhibitor, may reduce the metabolic clearance of lobeglitazone, which is primarily metabolized by CYP1A2. This can lead to increased plasma concentrations of lobeglitazone, potentially enhancing its therapeutic effects and risk of adverse events such as peripheral edema, weight gain, and hypoglycemia. Clinically, patients receiving both drugs should be monitored for signs of lobeglitazone toxicity, and dose adjustments may be necessary."
"Pirfenidone, an antifibrotic agent used for idiopathic pulmonary fibrosis, inhibits CYP1A2 isoenzyme activity, which is the primary metabolic pathway for theophylline. Concomitant administration can lead to a significant increase in theophylline serum concentrations, elevating the risk of theophylline toxicity, including nausea, vomiting, cardiac arrhythmias, and seizures. Clinical monitoring and dose adjustment of theophylline are necessary to avoid adverse effects."
"Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, may decrease the metabolic clearance of theophylline, a xanthine derivative bronchodilator, through competitive inhibition of cytochrome P450 (CYP) 1A2 enzymes. This interaction can lead to elevated serum theophylline concentrations, increasing the risk of theophylline toxicity, which may manifest as nausea, vomiting, arrhythmias, or seizures. Clinical monitoring and dose adjustment of theophylline are warranted to prevent adverse outcomes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOPHYL vs ACCURBRON, answered by our medical review team.
THEOPHYL is a Bronchodilator that works by Theophylline is a methylxanthine that causes bronchodilation primarily through inhibition of phosphodiesterase (PDE) and antagonism of adenosine receptors. It also has mild anti-inflammatory effects and enhances mucociliary clearance.. ACCURBRON is a Methylxanthine Bronchodilator that works by Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOPHYL and ACCURBRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOPHYL is: 300 mg orally every 6 hours or 400-600 mg extended-release orally every 12-24 hours; intravenous loading dose 5-6 mg/kg over 20-30 minutes, then continuous infusion 0.4-0.6 mg/kg/h. The standard adult dose of ACCURBRON is: Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOPHYL and ACCURBRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOPHYL is classified as Category C. Theophylline is not considered a major human teratogen. First trimester: Limited data show no increased risk of major malformations above baseline. Second and third trimesters: No . ACCURBRON is classified as Category C. No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.